ArticleNew microbes and new infections2025
Cardiorespiratory impact of COVID-19 in young adults: A propensity score-weighted cohort study.
Article in New microbes and new infections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The COVID-19 pandemic has raised concerns regarding persisting cardiorespiratory effects in young adults. This study aimed to assess the impact of COVID-19 on cardiopulmonary function in this population. Methods: This investigation, using data from the LoCoMo study, evaluated young recruits from the Swiss Armed Forces, aged 18-30 years. Participants were categorized based on their SARS-CoV-2 infection status and underwent cardiopulmonary exercise testing (CPET), spirometry, and diffusion capacity tests (DLCO). Propensity score weighting adjusted for confounding factors compared key outcomes between the control and COVID-19 groups. Finding: We evaluated 242 participants in the control group and 240 in the COVID-19 group. The propensity score-weighted analysis showed no significant differences in most CPET and pulmonary outcomes. The COVID-19 group exhibited a significant reduction in systolic blood pressure (SBP) at peak exercise by 7.68 mmHg (p = 0.001), more pronounced in recent cases (<6 months, 14.60 mmHg, p = 0.002) and persisting after infection in non-recent cases (>6 months, 9.07 mmHg, p = <0.001). There was an increase in V'Epeak [% predicted MVV] by 2.92 % in the COVID-19 group, notably in the "non-recent" subgroup who had been infected more than 6 months previously (p = 0.003). Interpretation: Young adults can exhibit persisting cardiopulmonary effects post-COVID-19, including reduced systolic blood pressure at peak exercise and increased ventilatory response, likely due to deconditioning and muscle weakness. These findings underscore the importance of maintaining physical activity during recovery to mitigate these effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.